| Field | Specification |
|---|---|
| Target | |
| Alternative names | CD 33; CD33; CD33 antigen (gp67); CD33 antigen; CD33 molecule; CD33_HUMAN; FLJ00391; gp67; My9; Myeloid cell surface antigen CD33; Myeloid cell surface antigen CD33 precursor; Myeloid differentiation antigen CD33; p67; Sialic acid binding Ig like lectin 3; Sialic acid binding immunoglobulin like lectin 3; Sialic acid-binding Ig-like lectin 3; SIGLEC 3; Siglec-3; SIGLEC3 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | Recombinant Human Myeloid cell surface antigen CD33 protein (18-259AA) |
| Conjugate | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Purification | |
| Form | Liquid |
| Storage | |
| Storage buffer | |
| Catalog no. (Mfr.) | |
| Main SKU |
Overview
This polyclonal anti-CD33 antibody raised in Rabbit, conjugated with Biotin, tested in ELISA. Designed to detect CD33 in Human for immunology research.
Key elements and design rationale
- Immunogen: Recombinant Human Myeloid cell surface antigen CD33 protein (18-259AA) — determines epitope; confirm sample prep compatibility.
- Host (Rabbit): Requires anti-rabbit-IgG secondary matching isotype IgG.
- Polyclonal: Multiple epitopes = robust signal; lot-to-lot variability — include controls.
- Isotype (IgG): Match secondary, Protein A/G, and isotype controls to IgG.
- Purification (Protein G purification): Enriches Ig classes; reduces non-specific background.
- Biotin: Streptavidin/avidin amplification; block endogenous biotin in biotin-rich samples.
Biological background
CD33 (also: CD 33, CD33, CD33 antigen (gp67), CD33 antigen, CD33 molecule, CD33_HUMAN, FLJ00391, gp67, My9, Myeloid cell surface antigen CD33, Myeloid cell surface antigen CD33 precursor, Myeloid differentiation antigen CD33, p67, Sialic acid binding Ig like lectin 3, Sialic acid binding immunoglobulin like lectin 3, Sialic acid-binding Ig-like lectin 3, SIGLEC 3, Siglec-3, SIGLEC3) — studied in Human systems. Expression, localization, and PTMs vary across cell types and disease states. Consult UniProt, NCBI Gene, and primary literature for current CD33 annotation relevant to immunology.
Common research applications
- ELISA: Quantify soluble target; ensure samples within the linear detection range.
Notes for experimental interpretation
- Isotype controls: IgG from Rabbit at equivalent concentration.
- Cross-reactivity: Polyclonal: validate with KO/KD controls.
- Matrix effects: Verify dilution linearity in your sample matrix.
- Reactivity: Confirmed for Human; extrapolation requires validation.
This product is a polyclonal antibody purified from rabbit antiserum.
CD33 is a protein studied in Human biology. This polyclonal antibody raised in Rabbit detects CD33 in ELISA applications, IgG isotype.
Reported reactive against Human. Immunogen from Human. Cross-reactivity with untested species requires empirical confirmation.
Reported for ELISA. Optimize dilution/blocking per application. Consult datasheet for working concentrations.
Biotin: streptavidin/avidin amplification. Block endogenous biotin in biotin-rich samples.
(1) Isotype control: IgG from Rabbit; (2) Positive control: lysate/cell line expressing CD33; (3) Negative control: siRNA KD or KO; (4) Dilution linearity in your sample matrix.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
